Announcements Trials
Browse Landscape

Phase

Phase 2 55Phase 1 17Phase 3 10Phase 1/2 5Phase NA 3Phase 2/3 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1NET 1Endocrine 1

Conditions

Colorectal Neoplasms 13Carcinoma, Hepatocellular 6Colonic Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Uterine Cervical Neoplasms 2Rectal Neoplasms 2Ovarian Neoplasms 2Fallopian Tube Neoplasms 2Astrocytoma 2Vipoma 1Squamous Cell Carcinoma of Head and Neck 1Spinal Cord Neoplasms 1Somatostatinoma 1Small Cell Lung Carcinoma 1Recurrence 1Progression Free Survival 1Oropharyngeal Neoplasms 1Oesophagogastric Cancer 1Neuroendocrine Tumors 1Neoplasms 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1Mouth Neoplasms 1Mesothelioma 1Lymphoid Interstitial Pneumonia 1Lung Neoplasms 1Laryngeal Neoplasms 1Insulinoma 1Inflammatory Breast Neoplasms 1Hypopharyngeal Neoplasms 1

Interventions

Cisplatin 6Pemetrexed 5Carboplatin 5pembrolizumab 4Paclitaxel 4Magnetic Resonance Spectroscopy 4Docetaxel 4Gemcitabine 3Dexamethasone 3dexamethasone acetate 2dexamethasone 21-phosphate 2cemiplimab 2auricularum 2Specimen Handling 2Ramucirumab 2Radiotherapy 2Leucovorin 2Erlotinib Hydrochloride 2Drug Therapy 2Calcium Dobesilate 2pertuzumab 1oblimersen 1maimendongtang 1endostar protein 1cyclopropapyrroloindole 1cediranib 1aumolertinib 1anamorelin 1Vitamin B 12 1Vinorelbine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Lung Neoplasms × Bevacizumab × Clear all
NCT00227617 2023-05-22

Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors

University of California, San Francisco

Phase 2/3 Terminated
36 enrolled 14 charts
EndocrineNETThoracic

Vipoma, Glucagonoma, Insulinoma, Adenoma, Islet Cell, Lung Neoplasms, Neoplasms, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡